Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 6
2006 5
2007 10
2008 2
2009 8
2010 8
2011 20
2012 25
2013 39
2014 33
2015 29
2016 35
2017 43
2018 52
2019 52
2020 77
2021 69
2022 77
2023 54
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

590 results

Results by year

Filters applied: . Clear all
Page 1
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study.
Wang S, Wang Y, Zhu C, Liu K, Chao J, Zhang N, Piao M, Yang X, Zhang L, Long J, Xun Z, Zhang T, Sang X, Yang X, Zhao H. Wang S, et al. Among authors: yang x. Int J Surg. 2024 May 3. doi: 10.1097/JS9.0000000000001540. Online ahead of print. Int J Surg. 2024. PMID: 38704621
Synergistic suppression of BDNF via epigenetic mechanism deteriorating learning and memory impairment caused by Mn and Pb co-exposure.
Wei L, He H, Yang S, Shi Q, Wang X, Huang L, Lu J, Shen Y, Zhi K, Xiang J, Chen C, Mo J, Zheng Z, Zou Y, Yang X, Tang S, Li X, Lu C. Wei L, et al. Among authors: yang x. Ecotoxicol Environ Saf. 2024 Apr 23;277:116365. doi: 10.1016/j.ecoenv.2024.116365. Online ahead of print. Ecotoxicol Environ Saf. 2024. PMID: 38657452 Free article.
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.
Xu L, Chen J, Liu C, Song X, Zhang Y, Zhao H, Yan S, Jia W, Wu Z, Guo Y, Yang J, Gong W, Ma Y, Yang X, Gao Z, Zhang N, Zheng X, Li M, Su D, Chen M. Xu L, et al. Among authors: yang x. BMC Med. 2024 Apr 23;22(1):172. doi: 10.1186/s12916-024-03356-5. BMC Med. 2024. PMID: 38650037 Free PMC article. Clinical Trial.
590 results